Sugi Predict

Sugi Predict / Compounds / SCHEMBL992227

SCHEMBL992227

SCHEMBL992227

CC(C)(C)OC(=O)N1CCC(c2nc3ccccc3[nH]2)CC1

nearest known ligand 0.61

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 8/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ POLB P06746 1/20 0.57
▸ MAPT P10636 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ PDE10A Q9Y233 1/20 0.56
▸ PKM P14618 1/20 0.55
▸ HPGDS O60760 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24067409 0.88 HTR2B (0.59) HTR2BSMN1; SMN2POLBMAPTHSD17B10
SCHEMBL739188 0.88 HPGDS (0.57) HTR2BSMN1; SMN2POLBHPGDS
SCHEMBL19408169 0.88 HPGDS (0.57) HTR2BSMN1; SMN2POLBHPGDS
SCHEMBL762565 0.88 HPGDS (0.57) HTR2BSMN1; SMN2POLBHPGDS
SCHEMBL21714580 0.87 KMT2A (0.52) HTR2BSMN1; SMN2POLBMAPTHSD17B10
SCHEMBL19924942 0.86 POLB (0.64) HTR2BSMN1; SMN2POLBMAPTHSD17B10
SCHEMBL30852213 0.85 PDE10A (0.54) MAPTPDE10APKMHPGDS
SCHEMBL7718379 0.85 HPGDS (0.55) HTR2BSMN1; SMN2MAPTPDE10APKM
SCHEMBL17109171 0.85 USP2 (0.49) HTR2BMAPTHPGDS
SCHEMBL30496019 0.85 HPGDS (0.55) HTR2BSMN1; SMN2MAPTPDE10APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924240-A Synthesis process of 4- (1H-benzo [ D ] imidazole-2-yl) piperidine-1-carboxylic acid tert-butyl ester 江苏恒沛药物科技有限公司 2024-04-26 — — CN claimed
CN-106146459-B Preparation method of bilastine 山东罗欣药业集团恒欣药业有限公司 2019-12-20 — — CN claimed
WO-2025129167-A1 INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) 2025-06-19 — — WO disclosed
CN-117924240-A Synthesis process of 4- (1H-benzo [ D ] imidazole-2-yl) piperidine-1-carboxylic acid tert-butyl ester 江苏恒沛药物科技有限公司 2024-04-26 — — CN disclosed
CN-117924240-A Synthesis process of 4- (1H-benzo [ D ] imidazole-2-yl) piperidine-1-carboxylic acid tert-butyl ester 江苏恒沛药物科技有限公司 2024-04-26 — — CN disclosed
CN-117924240-A Synthesis process of 4- (1H-benzo [ D ] imidazole-2-yl) piperidine-1-carboxylic acid tert-butyl ester 江苏恒沛药物科技有限公司 2024-04-26 — — CN disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 — — EP disclosed
CN-115745954-A Preparation method of bilastine intermediate 山东新时代药业有限公司 2023-03-07 — — CN disclosed
CN-114591291-A Bilastine intermediate compound and preparation method thereof 鲁南制药集团股份有限公司 2022-06-07 — — CN disclosed
CN-114591292-A Bilastine intermediate compound 鲁南制药集团股份有限公司 2022-06-07 — — CN disclosed
US-11208397-B2 Small molecule antagonists of sumo related modification of CRMP2 and uses thereof ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2021-12-28 — — US disclosed
US-20100324024-A1 Quinolizidinone M1 Receptor Positive Allosteric Modulators MERCK SHARP & DOHME CORP. (US) 2010-12-23 — — US disclosed
EP-2240464-A2 PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS Yuhan Corporation (KR) 2010-10-20 — — EP disclosed
WO-2009102155-A2 PROCESS FOR PREPARATION OF 2-METHYL-2´-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE COMPOUNDS YUHAN CORPORATION (KR) 2009-08-20 — — WO disclosed
CN-101460223-A Quinolones as Inducible Nitric Oxide Synthase Inhibitors KALYPSYS INC (US) 2009-06-17 — — CN disclosed
WO-2007117778-A9 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS INC (US) 2009-05-22 — — WO disclosed
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2008-06-12 — — US disclosed
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2008-06-12 — — US disclosed
WO-2007117778-A2 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2007-10-18 — — WO disclosed
US-7244847-B2 Benzimidazole compounds ISIS PHARMACEUTICALS, INC. (US) 2007-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS NOS2, NOS1, NQO2 HTR2B 3435/4885SMN1; SMN2 4153/4885POLB 664/4885
US-11208397-B2 Small molecule antagonists of sumo related modification of CRMP2 and uses thereof SUMO2, SUMO1, SUMO3 HTR2B 1343/4885SMN1; SMN2 782/4885POLB 4435/4885
US-20100324024-A1 Quinolizidinone M1 Receptor Positive Allosteric Modulators CHRM1, CHRM2, OPRL1 HTR2B 63/4885SMN1; SMN2 2257/4885POLB 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.